2 citations
,
June 2020 in “BMC Health Services Research” This study found that after a health warning, off-label flutamide use by women reduced significantly in Spain, although misuse among ambulatory patients remains an issue.
This nested case-control study observed that patients with benign prostatic hyperplasia or androgenic alopecia who had a cumulative 5-ARI dose exceeding 5840 defined daily doses had a significantly reduced mortality risk, while lower doses were linked to higher mortality and suicide rates.
June 2026 in “EJC Paediatric Oncology” In this retrospective study on pediatric craniospinal irradiation, researchers found that permanent radiation-induced alopecia occurred in 45.8% of patients, with higher radiation doses and treatment intensity being significant predictors, suggesting that defined dosimetric thresholds can support scalp-sparing planning.
4 citations
,
January 2019 in “Dermatology Online Journal” This article discusses the potential of low-dose naltrexone as an adjuvant therapy for trichodynia in alopecias, noting its anti-inflammatory properties and need for further research.
March 2025 in “Scientific Reports” This study found a complex relationship between cumulative doses of 5-ARIs and all-cause mortality among BPH or AGA patients, with lower doses linked to higher suicide rates and higher doses reducing cardiovascular mortality risk.